Stephen Wiviott
Stephen Wiviott
Harvard Medical School
Verified email at
Cited by
Cited by
Prasugrel versus clopidogrel in patients with acute coronary syndromes
SD Wiviott, E Braunwald, CH McCabe, G Montalescot, W Ruzyllo, ...
New England Journal of Medicine 357 (20), 2001-2015, 2007
Edoxaban versus warfarin in patients with atrial fibrillation
RP Giugliano, CT Ruff, E Braunwald, SA Murphy, SD Wiviott, JL Halperin, ...
New England Journal of Medicine 369 (22), 2093-2104, 2013
Evolocumab and clinical outcomes in patients with cardiovascular disease
MS Sabatine, RP Giugliano, AC Keech, N Honarpour, SD Wiviott, ...
New England Journal of Medicine 376 (18), 1713-1722, 2017
Ezetimibe added to statin therapy after acute coronary syndromes
CP Cannon, MA Blazing, RP Giugliano, A McCagg, JA White, P Theroux, ...
New England Journal of Medicine 372 (25), 2387-2397, 2015
Dapagliflozin and cardiovascular outcomes in type 2 diabetes
SD Wiviott, I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, ...
New England Journal of Medicine 380 (4), 347-357, 2019
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
BM Scirica, DL Bhatt, E Braunwald, PG Steg, J Davidson, B Hirshberg, ...
New England Journal of Medicine 369 (14), 1317-1326, 2013
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium
R Mehran, SV Rao, DL Bhatt, CM Gibson, A Caixeta, J Eikelboom, S Kaul, ...
Circulation 123 (23), 2736-2747, 2011
Cytochrome p-450 polymorphisms and response to clopidogrel
JL Mega, SL Close, SD Wiviott, L Shen, RD Hockett, JT Brandt, JR Walker, ...
New England Journal of Medicine 360 (4), 354-362, 2009
Rivaroxaban in patients with a recent acute coronary syndrome
JL Mega, E Braunwald, SD Wiviott, JP Bassand, DL Bhatt, C Bode, ...
New England Journal of Medicine 366 (1), 9-19, 2012
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome …
TA Zelniker, SD Wiviott, I Raz, K Im, EL Goodrich, MP Bonaca, ...
The Lancet 393 (10166), 31-39, 2019
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents
L Mauri, DJ Kereiakes, RW Yeh, P Driscoll-Shempp, DE Cutlip, PG Steg, ...
New England Journal of Medicine 371 (23), 2155-2166, 2014
Long-term use of ticagrelor in patients with prior myocardial infarction
MP Bonaca, DL Bhatt, M Cohen, PG Steg, RF Storey, EC Jensen, ...
New England Journal of Medicine 372 (19), 1791-1800, 2015
Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel …
SD Wiviott, D Trenk, AL Frelinger, M O’Donoghue, FJ Neumann, ...
Circulation 116 (25), 2923-2932, 2007
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial
JA de Lemos, MA Blazing, SD Wiviott, EF Lewis, KAA Fox, HD White, ...
Jama 292 (11), 1307-1316, 2004
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events
MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, DJ Blom, J Robinson, ...
New England Journal of Medicine 372 (16), 1500-1509, 2015
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised …
G Montalescot, SD Wiviott, E Braunwald, SA Murphy, CM Gibson, ...
The Lancet 373 (9665), 723-731, 2009
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis
JL Mega, T Simon, JP Collet, JL Anderson, EM Antman, K Bliden, ...
Jama 304 (16), 1821-1830, 2010
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
ML O'Donoghue, E Braunwald, EM Antman, SA Murphy, ER Bates, ...
The Lancet 374 (9694), 989-997, 2009
Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis
MG Silverman, BA Ference, K Im, SD Wiviott, RP Giugliano, SM Grundy, ...
Jama 316 (12), 1289-1297, 2016
Vorapaxar in the secondary prevention of atherothrombotic events
DA Morrow, E Braunwald, MP Bonaca, SF Ameriso, AJ Dalby, MP Fish, ...
New England Journal of Medicine 366 (15), 1404-1413, 2012
The system can't perform the operation now. Try again later.
Articles 1–20